



JDRF INTERNATIONAL

Consolidated Financial Statements

June 30, 2020 and 2019

(With Independent Auditors' Report Thereon)



KPMG LLP
345 Park Avenue
New York, NY 10154-0102

Independent Auditors' Report

The Board of Directors
JDRF International:

We have audited the accompanying consolidated financial statements of JDRF International, which comprise the consolidated statements of financial position as of June 30, 2020 and 2019, and the related consolidated statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of JDRF International as of June 30, 2020 and 2019, and the changes in its net assets and its cash flows for the years then ended, in accordance with U.S. generally accepted accounting principles.

KPMG LLP

December 10, 2020

JDRF INTERNATIONAL

Consolidated Statements of Financial Position

June 30, 2020 and 2019

(In thousands)

Assets	2020	2019
Cash, cash equivalents and restricted cash	\$ 47,761	55,693
Investments (note 3):		
Operating investments	25,597	17,604
Long-term investments	78,186	80,183
Programmatic investments	50,042	21,444
Contributions and other receivable, net (note 7)	44,140	50,792
Programmatic notes receivable (note 8)	3,870	6,720
Prepaid expenses and other assets	7,022	6,103
Fixed assets, net (note 9)	11,405	5,895
Total assets	\$ <u>268,023</u>	<u>244,434</u>
Liabilities and Net Assets		
Liabilities:		
Accounts payable and accrued expenses	\$ 19,845	16,774
Loans payable (note 12)	5,000	—
Research grants payable (note 11)	99,239	100,066
Deferred revenue	7,731	9,233
Liabilities related to split-interest agreements	2,507	2,560
Total liabilities	<u>134,322</u>	<u>128,633</u>
Commitments and contingencies (note 12)		
Net assets:		
Without donor restrictions	85,539	76,838
With donor restrictions (notes 2(a) and 13)	48,162	38,963
Total net assets	<u>133,701</u>	<u>115,801</u>
Total liabilities and net assets	\$ <u>268,023</u>	<u>244,434</u>

See accompanying notes to consolidated financial statements.

JDRF INTERNATIONAL

Consolidated Statements of Activities

Years ended June 30, 2020 and 2019

(In thousands)

	2020			2019		
	Without donor restrictions	With donor restrictions	Total	Without donor restrictions	With donor restrictions	Total
Public support and revenue:						
Public support:						
Contributions	\$ 47,139	30,921	78,060	57,650	20,866	78,516
Events revenue:						
Proceeds	128,671	—	128,671	161,175	—	161,175
Direct donor benefits	(18,488)	—	(18,488)	(29,629)	—	(29,629)
Contributions from international affiliates (note 10)	6,449	—	6,449	6,981	—	6,981
Total public support	<u>163,771</u>	<u>30,921</u>	<u>194,692</u>	<u>196,177</u>	<u>20,866</u>	<u>217,043</u>
Revenue:						
Investment return, net	13,859	(38)	13,821	12,292	102	12,394
Other	1,672	—	1,672	2,313	—	2,313
Total revenue	<u>15,531</u>	<u>(38)</u>	<u>15,493</u>	<u>14,605</u>	<u>102</u>	<u>14,707</u>
Net assets released from restrictions	<u>21,684</u>	<u>(21,684)</u>	<u>—</u>	<u>21,401</u>	<u>(21,401)</u>	<u>—</u>
Total public support and revenue	<u>200,986</u>	<u>9,199</u>	<u>210,185</u>	<u>232,183</u>	<u>(433)</u>	<u>231,750</u>
Expenses:						
Program services:						
Research, net (note 11)	85,844	—	85,844	106,123	—	106,123
Public education and advocacy	50,681	—	50,681	53,426	—	53,426
Total program services	<u>136,525</u>	<u>—</u>	<u>136,525</u>	<u>159,549</u>	<u>—</u>	<u>159,549</u>
Supporting services:						
Management and general	21,093	—	21,093	21,303	—	21,303
Fundraising	34,667	—	34,667	31,502	—	31,502
Total supporting services	<u>55,760</u>	<u>—</u>	<u>55,760</u>	<u>52,805</u>	<u>—</u>	<u>52,805</u>
Total expenses	<u>192,285</u>	<u>—</u>	<u>192,285</u>	<u>212,354</u>	<u>—</u>	<u>212,354</u>
Change in net assets	8,701	9,199	17,900	19,829	(433)	19,396
Net assets at beginning of year	<u>76,838</u>	<u>38,963</u>	<u>115,801</u>	<u>57,009</u>	<u>39,396</u>	<u>96,405</u>
Net assets at end of year	<u>\$ 85,539</u>	<u>48,162</u>	<u>133,701</u>	<u>76,838</u>	<u>38,963</u>	<u>115,801</u>

See accompanying notes to consolidated financial statements.

JDRF INTERNATIONAL

Consolidated Statements of Cash Flows

Years ended June 30, 2020 and 2019

(In thousands)

	2020	2019
Cash flows from operating activities:		
Change in net assets	\$ 17,900	19,396
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Net appreciation in fair value of investments	(11,173)	(9,946)
Depreciation and amortization	4,192	3,926
Deferred rent credits	2,259	(456)
Other revenue-conversion to equity	(1,198)	—
Changes in operating assets and liabilities:		
Contributions and other receivables	6,652	(118)
Prepaid expenses and other assets	(919)	(112)
Noncapital accounts payable and accrued expenses	105	(5,121)
Research grants payable	(827)	5,146
Deferred revenue	(1,502)	(819)
Liabilities related to split-interest agreements	(53)	(65)
Net cash provided by operating activities	15,436	11,831
Cash flows from investing activities:		
Purchase of fixed assets	(9,702)	(2,492)
Change in accounts payable and accrued expenses related to fixed asset acquisitions	707	—
Funding of programmatic investments	(29,660)	(3,463)
Proceeds from sale of programmatic investments	12,693	3,415
Conversion (disbursement) of programmatic notes	2,850	(5,220)
Purchase of operating investments	(49,382)	(25,797)
Proceeds from sale of operating investments	42,129	25,344
Purchase of long-term investments	(260)	(51,650)
Proceeds from sale of long-term investments	2,257	49,823
Net cash used in investing activities	(28,368)	(10,040)
Cash flows from financing activities:		
Proceeds from line of credit	5,000	—
Net cash provided by financing activities	5,000	—
Change in cash and cash equivalents	(7,932)	1,791
Cash and cash equivalents at beginning of year	55,693	53,902
Cash and cash equivalents at end of year	\$ 47,761	55,693

See accompanying notes to consolidated financial statements.

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

(1) Organization

JDRF International (JDRF) is the leading global nonprofit organization funding type 1 diabetes (T1D) research with a mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications. JDRF maintains an in-house team of experts that identifies the most promising strategies to fulfill its mission. Over the decades, JDRF's work has resulted in significant developments in the understanding of the disease—bringing us closer to prevention and a cure—and better treatment options for people with T1D.

In addition to direct research funding, JDRF is able to leverage its influence to attract hundreds of millions of dollars more in follow-on investments by third parties to the T1D space each year. JDRF's ability to create funding partnerships and attract follow-on funding is a direct reflection of the credibility, success and influence that has been established over five decades. By leveraging relationships, JDRF helps generate a greater number of innovative approaches to curing, preventing and better treating T1D.

JDRF solicits contributions from the public and engages in various fundraising activities. Funds raised are used principally to support T1D research. Furthermore, JDRF promotes public education initiatives and advocates for U.S. and foreign government funding of T1D research and raises awareness among Members of Congress of the financial, medical, and emotional costs of the disease.

Since 1997, JDRF has helped secure nearly \$3 billion in Federal funding for T1D research through the Special Diabetes Program. This program—administered by the National Institutes of Health—has produced tangible results in advancing cure therapies, prevention studies, and treatments—including artificial pancreas technology and groundbreaking advances in vision improvement among people with diabetic eye disease. JDRF also advocates for regulatory and health policies, which enable research to proceed without delay and provide widespread access to life-changing T1D therapies.

JDRF drives early stage commercial investment in T1D therapies through an independently managed venture philanthropy fund. JDRF T1D Fund LLC (The Fund), formerly JDRF Therapeutics Fund LLC, is a limited liability company whose sole member is JDRF and was activated during the year ended June 30, 2016 and is considered a disregarded entity of JDRF. The purpose of The Fund is to materially accelerate the development of drugs, devices, diagnostics, and vaccines to treat, prevent, and cure T1D. The Fund provides funding to companies and institutions conducting such T1D research and development through investment capital or other commercial agreements using donations made to The Fund and monies provided by JDRF.

JDRF financial results are presented on a consolidated basis, including JDRF and The Fund. All significant inter-company balances and transactions have been eliminated in consolidation.

JDRF's consolidated financial statements include the accounts of The Fund and JDRF Chapters located throughout the United States. International affiliates are in Canada, Australia, the United Kingdom, and several other countries. The financial statements of these international affiliates are not included in the accompanying consolidated financial statements since JDRF does not exercise control over their management or operations. However, international affiliates do provide contributions to JDRF to support funding of research grants as presented in note 10.

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

JDRF is a not-for-profit organization exempt from federal income taxes under Section 501(c)(3) of the Internal Revenue Code and is organized under the laws of the Commonwealth of Pennsylvania. The effect of income tax positions is recognized only if those positions are more likely than not of being sustained. Income generated from activities unrelated to JDRF's exempt purpose is subject to tax under Internal Revenue Code Section 511. Unrelated business income tax liability was insignificant for the years ended June 30, 2020 and 2019.

The spread of the coronavirus (COVID-19) around the world during 2020 has caused significant volatility in the U.S. and international markets. COVID-19 disrupted JDRF's event-based fundraising model and reduced its revenue. As a result, JDRF has accelerated new strategies to ensure its mission is met and its communities are served, becoming a more volunteer powered organization.

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation

JDRF's consolidated financial statements are prepared on the accrual basis of accounting in accordance with standards established by the Financial Accounting Standards Board (FASB) for external financial reporting by not-for-profit organizations. Accordingly, net assets and changes therein are classified and reported as follows:

Without donor restrictions – Net assets that are not subject to donor-imposed restrictions.

With donor restrictions – Net assets subject to donor-imposed restrictions that will be met either by actions of JDRF, by the passage of time or donor-imposed restrictions, and donor-restricted endowment that stipulate that the principal be maintained permanently, but permit JDRF to expend part or all the income and gains derived therefrom.

Revenues and gains and losses on investments and other assets are reported as changes in net assets without donor restrictions unless limited by explicit donor-imposed restrictions or by law. Expenses are reported as decreases in net assets without donor restrictions.

When a time restriction ends or a purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statements of activities as net assets released from restrictions.

The composition of net assets with donor restrictions as of June 30, 2020 and 2019 is as follows:

	<u>2020</u>	<u>2019</u>
Future periods, principally pledges receivable, and split-interest agreements	\$ 38,590	30,240
Other contributions/purpose restricted	1,863	835
Perpetual endowment	<u>7,709</u>	<u>7,888</u>
	<u>\$ 48,162</u>	<u>38,963</u>

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

(b) Contributions

Contributions, including unconditional promises to give (pledges), are reported as revenues in the period received or pledged. Contributions with purpose or time restrictions are reported as increases in net assets with donor restrictions and are reclassified to net assets without donor restrictions when the purpose or time restrictions are met. Contributions subject to donor-imposed stipulations that the corpus be maintained permanently are recognized as increases in net assets with donor restrictions.

Unconditional promises to give are recognized initially at fair value as contributions revenue in the period such promises are made by donors. Fair value is estimated considering anticipated future cash receipts (after allowance is made for uncollectible contributions) and discounting such amounts at a treasury yield rate commensurate with the duration of the donor's payment plan. In subsequent periods, the discount rate is unchanged and the allowance for uncollectible contributions is reassessed and adjusted if necessary. Amortization of the discount is recorded as additional contribution revenue in accordance with the donor-imposed restrictions, if any, on the contribution.

A contribution is conditional if the agreement includes both a barrier that must be overcome for the recipient to be entitled to the assets transferred and a right of return for the transferred assets or a right of release of the promisor's obligations to the transferred assets. Conditional promises to give are not recognized until they become unconditional, that is, when the barriers on which they depend are met. Contributions of assets other than cash are recorded at their estimated fair value. Contributions expected to be received after one year are discounted at a treasury yield rate of return.

Contributions received for future events, primarily walk and ride events, are recorded as deferred revenue and are recognized as revenue in the fiscal year the event takes place, which is generally within one year.

JDRF administers two types of split-interest agreements—Charitable Gift Annuities and Charitable Remainder Trusts. With Charitable Gift Annuities, cash or marketable securities are received from a donor in exchange for an annuity to be distributed for a fixed amount over the lifetime or lifetimes of the donor or other beneficiaries. With Charitable Remainder Trusts administered by JDRF, donated assets are received under a trust agreement established by the donor in exchange for an income stream to be distributed to the donor and/or other beneficiaries over a specified period. The distribution to the donor or other beneficiaries may be a fixed dollar amount (an annuity trust) or percentage of the fair value of the trust as determined annually (unitrust). For both Charitable Gift Annuities and Charitable Remainder Trusts, a related liability is recorded for the actuarially determined present value of the obligation to the annuitant or annuitants. The discount rates used to calculate the liability range between 1.2% and 8% at June 30, 2020. For Charitable Gift Annuities, the assets received are held by JDRF as general assets and the annuity liability is a general obligation.

(c) Cash and Cash Equivalents

Cash equivalents consist of securities purchased with original maturities of three months or less, except for such instruments purchased by JDRF's investment managers as part of their long-term investment strategy and those managed internally as part of JDRF's operating investments portfolio (see note 2(d)).

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

(d) Investments

Investments include (i) Long-term investments made to increase earnings for support of JDRF's mission and investments which support underlying planned giving and endowment agreements; (ii) Programmatic investments made to provide equity capital to companies to materially accelerate the development of drugs, devices, diagnostics, and vaccines to treat, prevent, and cure T1D, and (iii) Operating investments.

The purpose of the operating investments is to earn an average yield above of that available from the commercial U.S. government money market fund while minimizing the risk of market-related loss over a one year horizon. Operating investments are reported at fair value and includes cash and securities with varying original maturity dates, both lesser than and greater than three months.

Long-term investments in debt and equity securities, including assets related to split-interest agreements, with readily determinable fair values are reported at fair value based upon quoted market prices. Investments in funds, which report net asset value (NAV) or its equivalent (NAV funds), are reported at estimated fair value. The estimated fair value of NAV funds, as a practical expedient, is the NAV as provided by the investment managers, and evaluated for reasonableness by JDRF. Due to the inherent uncertainties of these estimates, these values may differ from the values that would have been used had a ready market existed for such investments.

Programmatic investments in equity securities are recorded at fair value.

As of June 30, 2020, JDRF T1D Fund invested \$53,912 in privately held companies with type 1 diabetes (T1D) related projects, of which \$50,042 are programmatic investments (note 3) and \$3,870 are programmatic notes receivable (note 8). These programmatic investments and notes receivable were made to provide equity capital to directly fund companies conducting the T1D research and development; therefore, there was no research grant related expense recorded thereby, decreasing the functional allocation percentage on research related expenses in the total program services while increasing the activities of the T1D fund through these investments.

(e) Fixed Assets

Fixed assets, which consist of furniture, equipment, and leasehold improvements, are recorded at cost. Depreciation is provided on a straight-line basis over the estimated useful lives of the assets, which approximate 3 to 10 years for furniture and equipment. Leasehold improvements are amortized on a straight-line basis over the shorter of the life of the asset or the lease term.

(f) Fair Value

Assets and liabilities reported at fair value are required to be classified within a fair value hierarchy, which gives preference to the use of observable inputs over unobservable inputs. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

market participants on the measurement date. The three levels of the fair value hierarchy are as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that a reporting entity has the ability to access at the measurement date.
- Level 2 inputs are other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3 inputs are unobservable inputs used when little or no market data is available.

JDRF follows Accounting Standards Update (ASU) (Topic 820), *Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or its Equivalent)*, which removes the requirements to categorize within the fair value hierarchy all investments for which fair value is measured using the NAV per share practical expedient and removes the requirement to make certain disclosures for all investments that are eligible to be measured at fair value using the NAV per share practical expedient.

(g) Functional Allocation of Expenses

The costs of providing the various programs and other activities are allocated based on time and have been summarized on a functional basis. Accordingly, certain costs (depreciation and amortization and operation and maintenance of plant) have been allocated among the programs and supporting services areas that were benefited. As discussed in note 2(d), Programmatic investments provide equity capital to directly fund companies conducting T1D research and development that are completely tied to the mission. There was no research grant related expense recorded on those investments; therefore, they are not included in the calculation of the total functional expenses.

(h) Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingencies at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the year. Significant estimates made in the preparation of the consolidated financial statements include fair value of investments, net realizable value of contributions receivable, and functional expense allocation. Actual results could differ from those estimates.

(i) Recently Adopted Accounting Standard

During 2020, JDRF adopted, FASB Accounting Standards Update (ASU) No. 2018-08, *Not for Profit Entities: Clarifying the Scope and Accounting Guidance for Contributions Received and Contributions Made*, ASU No. 2014-09, *Revenue from Contracts with Customers* and ASU 2016-18, *Statement of Cash Flows: Restricted Cash*, and ASU No. 2016-15, *Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments*.

ASU No. 2018-08 helps an entity evaluate whether it should account for a grant (or similar transaction) as a contribution or as an exchange transaction. The ASU also clarifies and expands the criteria for determining whether a contribution is conditional, which may delay recognition of contribution revenue

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

(recipient) or expense (resource provider). The implementation of this ASU did not have a significant impact on the consolidated financial statements.

ASU No. 2014-09 introduces a five-step model and related application guidance for revenue recognition. The core principle of this standard is that an entity shall recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also provides guidance on when costs to obtain a contract can be capitalized. The implementation of this ASU did not have a significant impact on the consolidated financial statements.

ASU No. 2016-18 requires that a statement of cash flows explains the change during the period in the total cash, and cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The ASU has been applied retrospectively. The implementation of this ASU did not have a significant impact on the consolidated financial statements.

ASU No. 2016-15 requires entities to classify each cash receipts and payments as cash flow from operating, investing, or financing activities based on the nature of the cash flow. It also requires noncash investing and financing activities to be disclosed. The ASU has been applied retrospectively. The implementation of this ASU did not have a significant impact on the consolidated financial statements.

(j) Reclassifications

Certain prior year amounts have been reclassified to conform to the current year presentation.

(3) Investments

Investments (including operating, long-term, and programmatic investments) at June 30, 2020 and 2019 consisted of the following:

	<u>2020</u>	<u>2019</u>
Investments measured at fair value (Level 1):		
Cash and cash equivalents	\$ 197	135
Mutual funds:		
Equity	49,040	49,219
Fixed income	53,717	44,220
Programmatic investments measured at fair value:		
Preferred stock (Level 1)	7,408	8,470
Preferred stock (Level 3)	42,634	12,974
Investments measured at NAV:		
Hedge funds	829	4,213
Total investments	<u>\$ 153,825</u>	<u>119,231</u>

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

Included in investments are amounts related to Charitable Gift Annuities and Charitable Remainder Trusts totaling \$2,723 and \$1,431, respectively, at June 30, 2020 and \$2,728 and \$1,539, respectively, at June 30, 2019.

Investments are exposed to various risks, such as market and credit risks. Because of such risks, it is possible that change in investment values could occur and that such changes could materially affect JDRF's consolidated financial statements.

Information with respect to the strategies of investments is as follows:

Preferred stock – The Fund made investments in private and public companies for which it holds Series of Preferred Stocks to provide equity capital to help materially accelerate the development of drugs, devices, diagnostics, and vaccines to treat, prevent, and cure T1D. As of June 30, 2020, there are no unfunded contingent commitments to programmatic investments.

Hedge funds – Investments in one fund that employ “alternative” strategies, primarily involving marketable securities. In addition to stocks and bonds, financial instruments traded by these funds may include derivatives contracts (e.g., futures, forwards, swaps, and options related to stocks, bonds, commodities, interest rates, or currencies), or less liquid assets such as private placements, structured products, bank loans, real estate, and special-purpose vehicles. These funds often employ the use of leverage and short selling. This investment is on full liquidation in fiscal year 2020 with a minimal balance left as of June 20, 2020 due to lock up.

JDRF's ability to redeem or sell its investments in NAV fund is based upon the terms and conditions in effect. NAV funds can be redeemed or sold annually.

There were no unfunded commitments as of June 30, 2020 and 2019.

The following table represents a reconciliation for all Level 3 assets measured at fair value:

	<u>Amounts</u>
Balance at July 1, 2018	\$ 11,261
Additions	4,213
Transfer out	<u>(2,500)</u>
Balance at July 1, 2019	12,974
Additions	29,660
Transfer out	<u>—</u>
Balance at June 30, 2020	<u>\$ 42,634</u>

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

(4) Liquidity and Availability of Resources

At June 30, 2020 and 2019, the Foundation's financial assets available within one year for general expenditures, such as program expenses and other operating expenses, are as follows:

	<u>2020</u>	<u>2019</u>
Cash and cash equivalents	\$ 47,761	55,693
Operating investments	25,597	17,604
Long-term investments	78,186	80,183
Programmatic investments	50,042	21,444
Contribution and other receivables, net	44,140	50,792
Total financial assets	<u>245,726</u>	<u>225,716</u>
Less those unavailable for general expenditure within one year:		
Time-restricted pledges due in greater than one year, net	19,794	12,784
Other contribution receivable, net	1,634	14,767
Donor-restricted endowment	7,709	7,888
Investments related to split interest agreements	4,154	4,267
Programmatic investments (Level 3)	42,634	12,974
Investment subject to lock-ups greater than one year	829	341
Total financial assets unavailable for general expenditures within one year	<u>76,754</u>	<u>53,021</u>
Total financial assets available to meet general expenditures within one year	<u>\$ 168,972</u>	<u>172,695</u>

(5) Retirement Plans

JDRF maintains a Tax Deferred Annuity Plan (403(b)) which allows employees to defer a portion of their wages for saving for retirement. The plan provides an annual employer matching contribution. To receive employer matching contributions, an eligible employee must be employed by JDRF on the last day of the Plan year.

This Plan was amended effective June 30, 2020, to suspend the annual discretionary employer matching contribution, due to the financial impact of COVID-19 as authorized by the Cares Act and, as a result of the Cares Act legislation, employees were eligible to take distributions of up to 100% of their account balance, under the Hardship withdrawal option. Related contribution expense for the years ended June 30, 2020 and 2019 was \$0 and \$1,836, respectively.

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

(6) Allocation of Joint Costs

JDRF allocates joint costs between fund-raising and program services or management and general in accordance with Accounting Standards Codification Subtopic (ASC) No. 958-720, *Accounting for Costs of Activities of Not-for-Profit Organizations and State and Local Governmental Entities That Include Fundraising*. In 2020 and 2019, JDRF conducted activities, principally direct mail, that included fundraising appeals as well as program components. The joint costs incurred were allocated as follows:

	2020	2019
Public education and advocacy	\$ 501	526
Fundraising	1,504	1,526
Total	\$ 2,005	2,052

(7) Contributions Receivable

Contributions receivable include pledges due in future periods, uncollected events revenues, and affiliate contributions receivable.

Contributions and other receivables at June 30, 2020 and 2019 consisted of the following:

	2020	2019
Gross pledges receivable, due in:		
Less than one year	\$ 19,864	17,482
One to five years	21,149	14,408
	41,013	31,890
Less:		
Allowance for doubtful accounts	(1,100)	(1,210)
Unamortized discount to present value, at rates ranging from 0.16% to 5.1%	(255)	(414)
Pledges receivable, net	39,658	30,266
Other contributions receivable, net	1,634	14,767
Events revenues receivables	2,848	5,759
	\$ 44,140	50,792

At June 30, 2020 and 2019, ten donors represented 29% and 35% of the total outstanding contributions and other receivables, respectively.

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

(8) Programmatic Notes Receivable

Programmatic notes receivable represents loans made to companies to provide capital to materially accelerate the development of drugs, devices, diagnostics, and vaccines to treat, prevent, and cure T1D. As of June 30, 2020 and 2019, the Fund has three and four, respectively, convertible promissory notes with private companies. The promissory notes bear interest and are convertible into shares of the company's preferred stock under certain conditions. The notes receivable are recorded at net realizable value at June 30, 2020 and 2019. The programmatic notes receivables have interest rate ranging from 5%–8%.

(9) Fixed Assets

Fixed assets at June 30, 2020 and 2019 consisted of the following:

	<u>2020</u>	<u>2019</u>
Furniture and equipment	\$ 15,578	23,388
Leasehold improvements	5,270	4,936
	<u>20,848</u>	<u>28,324</u>
Less accumulated depreciation and amortization	<u>(9,443)</u>	<u>(22,429)</u>
Fixed assets, net	<u>\$ 11,405</u>	<u>5,895</u>

As of June 30, 2020, fully depreciated assets of \$17,178 were written off.

(10) Contributions from International Affiliates

During the years ended June 30, 2020 and 2019, JDRF received contributions from affiliates as follows:

	<u>2020</u>	<u>2019</u>
JDRF – Canada	\$ 2,254	3,674
JDRF – United Kingdom	2,343	2,185
JDRF – Australia	<u>1,852</u>	<u>1,122</u>
	<u>\$ 6,449</u>	<u>6,981</u>

In April 2018, JDRF and the Affiliates reached an agreement on a renewed five-year Affiliate Agreement, with an option for a five-year renewal, with all agreements to expire in 2023. The Agreement remains much the same as the previous agreement but with the addition of a provision for termination with and termination without cause.

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

(11) Research Grants Payable

Research grants payable at June 30, 2020 and 2019 consisted of the following:

	<u>2020</u>	<u>2019</u>
Amounts expected to be paid in:		
Less than one year	\$ 84,546	80,561
One to five years	<u>14,719</u>	<u>20,013</u>
Subtotal	99,265	100,574
Less discount to present value, at rates ranging from 0.16% to 2.33%	<u>(26)</u>	<u>(508)</u>
Total	<u>\$ 99,239</u>	<u>100,066</u>

Research grant expense is net of any grant refunds, reductions, or terminations. These adjustments were \$5,762 and \$8,454 for the years ended June 30, 2020 and 2019, respectively.

(12) Commitments and Contingencies

(a) Research Grants

As of June 30, 2020, JDRF's conditional research grants commitments, including milestone contracts, of \$82,834, which will be recognized in the consolidated financial statements when the conditions have been met, are currently estimated to be payable as follows:

2021	\$ 43,662
2022	23,849
2023	10,207
2024	<u>5,116</u>
	<u>\$ 82,834</u>

(b) Leases

JDRF is obligated under various leases for space occupied by certain chapters and headquarters in New York. Rent expense, including maintenance costs for the chapters, was \$4,338 and \$4,165 for the years ended June 30, 2020 and 2019, respectively.

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

Rental commitments for all leases are as follows:

2021	\$	6,601
2022		5,799
2023		5,360
2024		4,632
2025		3,440
2026 and beyond		<u>14,206</u>
	\$	<u>40,038</u>

Rent expense is recognized on a straight-line basis, and accordingly, a deferred rent credit has been recorded. At June 30, 2020 and 2019, a credit of approximately \$2,971 and \$714, respectively, is included in accounts payable and accrued expenses.

(c) Line of Credit

On January 23, 2013, JDRF entered into an agreement with a financial institution for an unsecured line of credit in the aggregate amount of \$5 million. The line was used in fiscal year 2020 and \$5 million and \$0 was outstanding at June 30, 2020 and 2019, respectively. The line of credit expires January 31, 2021. Interest paid and accrued as of June 30, 2020 was \$45.

(13) Endowment

JDRF's endowment consists of seven individual donor-restricted endowment funds established for a variety of purposes. The Commonwealth of Pennsylvania has not enacted a version of the Uniform Prudent Management of Institutional Funds Act (UPMIFA), or a version of the Uniform Management of Institutional Funds Act (UMIFA). Governing law resides in 15 Pa. C.S. § 5548, *Investment of Trust Funds*. JDRF has interpreted Pennsylvania law as requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, net assets with donor restrictions of a perpetual nature include (a) the original value of gifts to the donor-imposed endowment and (b) accumulations of investment returns to the donor-imposed endowment made in accordance with the direction of the applicable donor gift instrument, when applicable until appropriated for expenditure. The endowment funds are invested in SEC registered, institutional quality mutual funds across a range of diversified asset classes including domestic and international large and small cap stocks, emerging markets equities, domestic and international REITs, domestic and foreign bonds, and investment grade and high yield bonds.

JDRF INTERNATIONAL

Notes to Consolidated Financial Statements

June 30, 2020 and 2019

(In thousands)

The following tables present the changes in donor-restricted endowment funds:

	With donor restrictions	
	2020	2019
Endowment net assets at beginning of year	\$ 7,888	7,568
Contribution	—	221
Investment income	33	3
Net (depreciation) appreciation	(71)	99
Appropriation for expenditure	(141)	(3)
Endowment net assets at end of year	\$ <u>7,709</u>	<u>7,888</u>

(14) Subsequent Events

In connection with the preparation of the consolidated financial statements, JDRF evaluated subsequent events after the consolidated statement of financial position date of June 30, 2020 through December 10, 2020, the date the consolidated financial statements were available for issuance. JDRF received funding from the CARES Act Small Business Loan Program subsequent to year end. No other additional disclosures are noted.